RibaPak had its day of importance in dual therapy, great innovation from RH in all reality. That said, take a look at the data from the daa's: just give 600qd via the generics once anemia smacks the pts down. No superiority data and the preferred SP sweetheart deals of old while missing the importance of or inability to contract with large pbms/insurance companies have caught up. If you want to be a big player, you have to play ball and rebate ect like all major pharma outfits do. With all the contractual business and state medicaids kicking off and ins co's flat out blocking due to high cost relative to generics, all that is left to do is try to stop the bleeding as best you can. Good luck! So glad to have moved on and not have to try and fight the "common sense compliance stance" that sells it. Would not be surprised to see them cut everyone and hold on to the current revenue to keep this place afloat until something in the pipeline eventually hits. Do you really think they are going to launch an oncology product with the current sales force? Get the ol resumes ready and polished along with your story of well it really was about trying to not lose marketshare, not necesarrily gaining any after a year of sellling. Anyone not already convinced to Rx rbk sure as hell isn't going to start now.